NeuroOne Medical Technologies Corporation
NMTCHealthcareNASDAQMedical Devices · Last scanned Sep 7, 2026
Scan Results
Daily timeframeNeuroOne Medical Technologies Corporation, a medical technology company, provides solutions for continuous electroencephalogram (cEEG) and stereoelectrocencephalography (sEEG) recording in the United. At a $14.8M market cap, NeuroOne Medical Technologies Corporation ranks as a micro-cap company within healthcare. The company also provides solutions for spinal cord stimulation, brain stimulation, drug delivery and ablation solutions for patients suffering from epilepsy, trigeminal neuralgia, Parkinson's disease, dystonia, essential tremors, and chronic pain due to failed back surgeries and other pain-related neurological disorders.
Market Cap
$14.8M
Beta
0.64
P/E (TTM)
—
P/E (Fwd)
-5.79
EPS (TTM)
$-0.97
EPS (Fwd)
$-0.28
ROE
-124.7%
ROA
-58.1%
Cash
$2.0M
Total Debt
$175,345
Free CF
-$4.6M
52W Change
-68.2%
Annual Financials
Cash vs Debt
Where NMTC stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, NMTC finished 53.87% below its 150-day moving average ($3.62) and 56.62% below its 200-day moving average ($3.85). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is NMTC overbought or oversold?
At the September 3, 2026 close, NMTC's RSI(14) was 44.1, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $2.0M in cash and $175K in debt, NMTC maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$4.6M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -124.7% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $171K (2022) to $9.1M (2025), reflecting a 5215% increase over the period.
NMTC's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. With cash comfortably exceeding debt, NMTC has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for NeuroOne Medical Technologies Corporation and its sector.